Third Federal COPD Workshop



Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of all deaths in the U.S., the most recent available data showing it was the primary cause of death for >76,000 women and >68,000 men  45 and over in 2013 (CDC Wonder accessed on September 24, 2015). The disease affects a large portion of the adult U.S. population, 6.5% of those aged 25 years and older, corresponding to approximately 14million people (60% of whom are women), according to data obtained through the CDC Behavioral Risk Factor Surveillance System (BRFSS) for 2011 and the default intercensal population data. This high COPD prevalence translates into frequent physician office and emergency department visits and hospitalizations (see report and data). 

COPD is a multifaceted disease, and, while mostly related to present or past cigarette smoking, approximately 15% of COPD occurs in individuals who have never smoked. There are gender and racial/ethnic differences in COPD prevalence and mortality. Characteristically, the individual with COPD is also affected by a variety of comorbid conditions that require precise, patient-tailored approaches to treatment.  The disease is responsible for frequent hospital and intensive care unit (ICU) admissions, and it decreases the likelihood of employment of the affected individuals, causing them to rely on the support of family caregivers.  Societal costs associated with COPD reached over $32 billion annually in direct health care costs and another $20 billion in morbidity and mortality (2010 data).

The huge burden of COPD within the US population has prompted long-standing research efforts both in the US and abroad and these have led to significant improvements in diagnosis and therapy for the disease. Notwithstanding these successes, the current epidemiological data clearly underscore the need for additional efforts to develop and implement new coordinated preventive, diagnostic, and therapeutic approaches.


Workshop Description

The teleconference began at 2:00 p.m. EST on September 10, 2015. The federal participants were informed of the intent of NHLBI to convene a public Town Hall meeting on February 29 and March 1st, 2016 in Bethesda, Maryland.   That meeting will be an opportunity for individuals who have COPD, their families, and all interested parties across the country to engage with other stakeholders and have a voice in shaping a COPD National Action Plan developed in response to encouragement from Congress.

To create a core agenda for the Town Hall meeting, six preliminary goals addressing the public health burden of COPD were presented and discussed. These goals originated from previous efforts led by CDC, and other organizations at the State or regional level, and from discussions NHLBI held internally and with various COPD stakeholders.

After discussions among federal partners, the six preliminary goals proposed were modified as follows:

  1. Empower patients,  their families, and communities to recognize and reduce the burden of COPD
  2. Increase and sustain prevention,  detection, diagnosis, treatment, and management of COPD
  3. Increase collaboration and coordination to sustain surveillance efforts and improve the collection, analysis, dissemination, and reporting of COPD-related public health data
  4. Increase and sustain research to better understand prevention, pathogenesis, diagnosis, treatment, and  management of COPD
  5. Increase awareness and sustain COPD education among stakeholders, decision makers, individuals with COPD, their families, caregivers, communities and  populations at risk
  6. Integrate recommended policy, educational, and program changes into the legislative, research, public health, and care delivery structures of the nation

These preliminary goals will serve as a starting point for an iterative process that will involve both federal COPD partners and other COPD stakeholders and will culminate in a national action plan for COPD.

These goals will provide a framework for discussions at a Town Hall meeting, planned for December 3-4, 2015. At that meeting each goal will be further developed to specify: a)Target Audience; b)Background; c) Short-Term and  Long-Term Objectives; d) Strategies; e) Benchmarks; and f)Available and Needed Resources.

Summary and Developments

COPD is a multifaceted disease, and approximately 15% of COPD occurs in individuals who have never smoked. There are gender and racial/ethnic differences in COPD prevalence and mortality. The disease is responsible for frequent hospital and ICU admissions. Societal costs associated with COPD surpassed $52 billion in 2010.

NHLBI, with the collaboration of other federal partners, recognizes the important contribution of diverse groups and organizations in efforts to reduce the burden of COPD. A Town Hall meeting is planned to enable coordination of goals and activities.

All stakeholders interested in contributing to the development of the plan, discuss its contents, and be active participants in its implementation, are invited to attend the Town Hall meeting (registration required).

By registering stakeholders will be able to:

Comment in advance on the proposed goals

Provide suggestions regarding plans for the meeting

Identify which goal(s) subgroup they want to attend

Receive detailed information regarding plans for the meeting (location, nearby lodging, etc.)

Registration Link 

Workshop Participants and Agencies/Institutes

Centers for Disease Control and Prevention (CDC)

  • Janet B. Croft, PhD

Centers for Medicare & Medicaid Innovation (CMMI-CMS)

  • Ron Kline MD

Food and Drug Administration (FDA)

  • Lydia I Gilbert McClain, MD, FCCP

Health Resources and Services Administration (HRSA)

Bureau of Primary Health Care

  • Preeta Chidambaran, MD, MPH

Health Resources and Services Administration (HRSA)

Federal Office of Rural Health Policy

  • Allison Hutchings, MPH

National Cancer Institute (NCI)

  • Judith J. Smith, MSN, RN, AOCN
  • Eva Szabo, MD

National Center for Health Statistics (NCHS-CDC)

  • Jennifer Madans, PhD

National Institute on Aging (NIA)

  • Sue Zieman, MD

National Institute on Drug Abuse (NIDA)

  • Elizabeth Lambert, PhD

National Institute of Environmental Health Sciences (NIEHS)

  • Dan Morgan, MD, MPH

National Institutes of Health (NIH), Office of the Director (OD)

Office of Disease prevention

  • Helen I Meissner ScM PhD
  • Rachel Ballard, MD

National Heart, Lung, and Blood Institute (NHLBI, organizing)

  • James P. Kiley, PhD
  • Jean Berube, JD
  • Thomas L. Croxton, PhD, MD
  • Lenora Johnson, PhD
  • Monique Ndenecho
  • Antonello Punturieri, MD, PhD
  • Lisa A. Postow, PhD
  • Mark Smolonsky
  • Lisa M. Viviano, BSN, RN

National Institute for Occupational Safety and Health (NIOSH)

  • David Weissman, MD

National Institute of Nursing Research (NINR)

  • Karen Huss, PhD, RN

Office of the Assistant Secretary of Defense (OASD, Health Affairs)

  • Robin Marzullo, RN, MS

Veterans Health Administration (VHA)

  • William C Yarbrough, MD